Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01572233
Other study ID # 201103086RC
Secondary ID
Status Recruiting
Phase N/A
First received April 4, 2012
Last updated December 26, 2012
Start date December 2011
Est. completion date June 2018

Study information

Verified date November 2012
Source National Taiwan University Hospital
Contact Siow-ching Shun, PhD
Phone 886-2-23123456
Email scshun@ntu.edu.tw
Is FDA regulated No
Health authority Taiwan: Department of Health
Study type Interventional

Clinical Trial Summary

This 4-year project will be guided by a biobehavioral model for the study of exercise interventions in two phases with the purposes to :

1. explore the patients' physical activity preferences and develop doable activity lists during treatment period

2. examine the changes of health-related physical fitness component over interferon treatment

3. develop the Personalized Physical Activity and Psych-Education (PPAPE) Program and test its effects on decreasing fatigue, physical and psychological distress, and improving their health-related physical fitness and quality of life in patients with chronic hepatitis C receiving Interferon with Ribavirin Combination Therapy

4. evaluate the outcome of the PPAPE program on increasing adherence to therapy, the sustained virological response (SVR) in 24 weeks after the end of treatment, and the time-consuming for education program during intervention.


Recruitment information / eligibility

Status Recruiting
Enrollment 300
Est. completion date June 2018
Est. primary completion date December 2017
Accepts healthy volunteers No
Gender Both
Age group 20 Years to 70 Years
Eligibility Inclusion Criteria:

- Patients with Chronic Hepatitis C Infection Receiving Interferon Therapy

- Aged above 18

Exclusion Criteria:

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care


Related Conditions & MeSH terms


Intervention

Behavioral:
Personalized Physical Activity and Psycho-Education (PPAPE) Program
Effects of Personalized Physical Activity and Psycho-Education Program on Patients with HCV infection The third and fourth year, will be examine on the 12, 24, 36, and 48 weeks during the interferon treatment.

Locations

Country Name City State
Taiwan National Taiwan University Hospital Taipei

Sponsors (2)

Lead Sponsor Collaborator
National Taiwan University Hospital National Health Research Institutes, Taiwan

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Effects of Activity and Education Program on Patients with Chronic Hepatitis C Infection Phase I of this project, the first and second year, the measurement time will be collected on the baseline (before treatment, T0), the 8 weeks (T1), 16 weeks (T2), and 24 weeks (T3) during treatment. 4-year project No
See also
  Status Clinical Trial Phase
Completed NCT04596475 - Prevention of Transmission of Hepatitis C Virus (HCV) From HCV-Viremic Organ Donor Phase 1/Phase 2
Recruiting NCT05361603 - Acceptability of Simultaneous Screening for Viral Hepatitis B, C and HIV Among Drug Users in Non-conventional Structures
Recruiting NCT05376943 - Possible Differences in HCC Course Depending on DAA Treatment
Recruiting NCT04251572 - HCV Reinfection After DAA Therapy in PWID in Belgium N/A
Completed NCT03369327 - Sofosbuvir and Daclatasvir for Treating Hepatitis C in 200 Patients Co-infected With Human Immunodeficiency Virus Phase 3
Recruiting NCT04768517 - HCV Reinfection in in HIV/HCV-coinfected Patients Achieving SVR by Antiviral Therapy
Recruiting NCT04732832 - HCV Reinfection in HD Patients Achieving SVR
Withdrawn NCT03381859 - Clinical Trial to eLiminate HCV-infection in Treatment-naïve, Renally Impaired EgyptiAn Patients on Renal Dialysis, With Chronic Hepatitis C Genotype 4 Phase 4
Recruiting NCT04677153 - Rapid HCV Treatment Access for Persons Who Use Drugs N/A
Completed NCT03453346 - Safety and Efficacy of Generic Sofosbuvir and Ribavirin for Treatment-naive Genotype 2 Chronic Hepatitis C N/A
Completed NCT02402218 - CHAMPS Study: Chronic HepAtitis C Management to ImProve OutcomeS N/A
Completed NCT01473056 - Study to Assess Safety,Tolerability,Pharmacokinetics & Antiviral Activity of JTK-853 in Hepatitis C Virus Genotype 1 Infected Subjects Phase 1
Completed NCT03250910 - Generic VEL/SOF With or Without RBV for HIV/HCV Coinfected Patients Phase 4
Enrolling by invitation NCT03343444 - Safety & Efficacy of Sofosbuvir 400mg/Ledipasvir 90mg in the Treatment of Chronic Hepatitis C Adolescents Phase 3